These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29683280)

  • 1. Hyperbaric oxygen therapy (HBOT )can improve the effectiveness of adalimumab in hidradenitis suppurativa.
    Marasca C; Vivona G; Annunziata MC; Cacciapuoti S; Capasso E; Ciotola A; Russo G; Fabbrocini G
    G Ital Dermatol Venereol; 2020 Apr; 155(2):234-235. PubMed ID: 29683280
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of hyperbaric oxygen therapy in the treatment of necrotizing soft tissue infections, compromised grafts and flaps, hidradenitis suppurativa, and pyoderma gangrenosum.
    Goggins CA; Khachemoune A
    Acta Dermatovenerol Alp Pannonica Adriat; 2019 Jun; 28(2):81-84. PubMed ID: 31233172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination hyperbaric oxygen therapy and ustekinumab for severe hidradenitis suppurativa.
    Provini LE; Stellar JJ; Stetzer MN; Nguyen PD; Jen M
    Pediatr Dermatol; 2019 May; 36(3):381-383. PubMed ID: 30805965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions for Hidradenitis Suppurativa: Updated Summary of an Original Cochrane Review.
    Ingram JR
    JAMA Dermatol; 2017 May; 153(5):458-459. PubMed ID: 28355440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hidradenitis suppurativa in Crohn's disease during adalimumab therapy: a paradox?
    Martina E; Campanati A; Giuliodori K; Offidani A
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Mar; 26(1):21-23. PubMed ID: 28352932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncommon pretibial bilateral manifestation of Hidradenitis suppurativa (Hurley III) after discontinuation of systemic treatment with adalimumab: a serious reason to prefer surgery as a primary approach?
    Tchernev G; Temelkova I; Wollina U
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):e449-e451. PubMed ID: 31273867
    [No Abstract]   [Full Text] [Related]  

  • 7. Hyperbaric oxygen therapy as an adjunct to surgical treatment of extensive hidradenitis suppurativa.
    Uzun G; Ozdemir Y; Mutluoğlu M; Güleç B
    World J Surg; 2010 Apr; 34(4):861-2; author reply 863. PubMed ID: 20012284
    [No Abstract]   [Full Text] [Related]  

  • 8. Low-dose adalimumab biosimilar (ZRC-3197) in the treatment of hidradenitis suppurativa.
    Patil S
    Indian J Dermatol Venereol Leprol; 2018; 84(6):745-747. PubMed ID: 30289113
    [No Abstract]   [Full Text] [Related]  

  • 9. A prospective randomized controlled trial assessing the efficacy of adjunctive hyperbaric oxygen therapy in the treatment of hidradenitis suppurativa.
    Yildiz H; Senol L; Ercan E; Bilgili ME; Karabudak Abuaf O
    Int J Dermatol; 2016 Feb; 55(2):232-7. PubMed ID: 26267600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe refractory hidradenitis suppurativa successfully treated with adalimumab in an HIV-positive/hepatitis C virus-positive patient.
    Molina-Leyva A; Badiola J
    AIDS; 2018 Oct; 32(16):2436-2438. PubMed ID: 30281563
    [No Abstract]   [Full Text] [Related]  

  • 11. Hidradenitis suppurativa in a patient with Warkany syndrome: Sustainability of adalimumab treatment.
    Atzori L; Bonato F; Pilloni L; Rongioletti F
    Dermatol Ther; 2020 Jan; 33(1):e13160. PubMed ID: 31705612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
    Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
    J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience.
    Bettoli V; Manfredini M; Calamo G; Forconi R; Bencivelli D; Mantovani L; Pellacani G; Corazza M
    Dermatol Ther; 2018 Nov; 31(6):e12737. PubMed ID: 30295378
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.
    Tzanetakou V; Stergianou D; Giamarellos-Bourboulis EJ
    Expert Opin Drug Saf; 2020 Apr; 19(4):381-393. PubMed ID: 32098513
    [No Abstract]   [Full Text] [Related]  

  • 16. Cellulitis-like Sweet Syndrome caused by adalimumab therapy for severe hidradenitis suppurativa.
    Canal Garcia E; Vargas Ramos JDP; Aguayo Ortiz R
    Australas J Dermatol; 2020 Nov; 61(4):e448-e449. PubMed ID: 32567672
    [No Abstract]   [Full Text] [Related]  

  • 17. Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab.
    Gunter SJ; Holcomb ZE; Lam BD; Porter ML; Kimball AB
    JAMA Dermatol; 2024 Jun; 160(6):678-681. PubMed ID: 38717768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective.
    Bi Y; Liu J; Wang J; Epps RE; Kettl D; Marcus K; Seo S; Zhu H; Wang Y
    AAPS J; 2019 Jul; 21(5):91. PubMed ID: 31325056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.
    Arenbergerova M; Gkalpakiotis S; Arenberger P
    Int J Dermatol; 2010 Dec; 49(12):1445-9. PubMed ID: 21091684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Genetic Variant in the BCL2 Gene Associates with Adalimumab Response in Hidradenitis Suppurativa Clinical Trials and Regulates Expression of BCL2.
    Liu M; Degner J; Georgantas RW; Nader A; Mostafa NM; Teixeira HD; Williams DA; Kirsner RS; Nichols AJ; Davis JW; Waring JF
    J Invest Dermatol; 2020 Mar; 140(3):574-582.e2. PubMed ID: 31465739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.